The initial patient is at the Dr. Kamakshi Memorial Medical center in Chennai. Related StoriesViralytics enters into clinical trial collaboration agreement with MSDOvarian cancer patients with a brief history of oral contraceptive use have got better outcomesMD Anderson study reveals why chemotherapy medicines not effective for most pancreatic tumor patientsThe U.S. National Cancer tumor Institute’s Gynecologic Oncology Group offers conducted 16 scientific trials in over 500 patients using various therapeutic regimens in this patient people and found the very best regimen tested resulted in a median survival of approximately 6 months and a 12 months survival of 5 percent.The patch is applied once every week for three weeks accompanied by a patch-free of charge week. We anticipate enrollment in to the scholarly research will be fast, powered by women’s desire for greater convenience and ease of compliance in their selection of contraception. KlegermanAgile’s NEW CHOICE Study will enroll up to 1500 women aged 17-40 at over 100 sites throughout the U.S. The NEW CHOICE Study will evaluate tolerability and efficacy of AG200-15 to a low-dose, oral contraceptive. Women interested in participating in the brand new CHOICE research should visit Dr.